Outpatient medical properties

Search documents
Better Dividend Stock: Healthpeak Properties vs. AGNC Investment
The Motley Fool· 2025-05-20 07:04
Core Viewpoint - Real estate investment trusts (REITs) can provide significant dividend yields, with AGNC Investment and Healthpeak Properties being highlighted for their monthly dividends, but their sustainability and growth potential differ significantly [1]. Group 1: AGNC Investment - AGNC Investment is a mortgage REIT that invests in Agency MBS, which are protected against credit risk by government agencies, and it employs leverage to enhance returns, resulting in a high monthly dividend yield of 15.7% [3]. - The CEO noted that the outlook for agency MBS investments remains favorable, with potential returns in the low-20% range, which exceeds the company's total cost of capital of approximately 18% [4]. - However, AGNC has previously cut its dividend when returns fell below costs, indicating that it may not be the best option for investors seeking a highly sustainable income stream [5]. Group 2: Healthpeak Properties - Healthpeak Properties is a healthcare REIT with a diversified portfolio that includes outpatient medical, lab, and senior housing properties, providing stable cash flow with contractual annual rental increases [7]. - The REIT's adjusted funds from operations (FFO) have grown by 19% over the past three years, and it expects to generate between $1.81 and $1.87 per share of FFO this year, comfortably covering its $1.22-per-share dividend [9]. - Healthpeak has a strong balance sheet with $500 million to $1 billion available for new investments, and it recently raised its dividend payout by 2%, indicating a capacity for future dividend increases [10][12].
Physicians Realty Trust(DOC) - 2025 Q1 - Earnings Call Transcript
2025-04-25 23:01
Healthpeak Properties (DOC) Q1 2025 Earnings Call April 25, 2025 07:01 PM ET Company Participants Andrew Johns - Senior Vice President, Investor RelationsScott Brinker - CEO, President & DirectorKelvin Moses - CFOFarrell Granath - Equity Research AssociateScott R. Bohn - Chief Development Officer and Co-Head of Life ScienceSeth Bergey - Senior Research AssociateRich Anderson - Managing DirectorVikram Malhotra - Managing DirectorMichael Carroll - Managing Director & Head of US Real Estate ResearchRobin Hanel ...
Healthpeak's Q1 FFO Meets Estimates, Same-Store NOI Rises
ZACKS· 2025-04-25 11:50
Core Viewpoint - Healthpeak Properties, Inc. reported first-quarter 2025 funds from operations (FFO) as adjusted per share of 46 cents, meeting expectations and showing a slight increase from 45 cents in the prior year, driven by better-than-anticipated revenues despite higher interest expenses [1][2]. Financial Performance - The company generated revenues of $702.9 million, exceeding the Zacks Consensus Estimate of $691.9 million, representing a year-over-year increase of 15.9% [2]. - Healthpeak reported a 7% year-over-year growth in total merger-combined same-store cash (adjusted) net operating income (NOI) [3]. - The outpatient medical and lab segments experienced year-over-year growth of 5% and 7.7%, respectively, while the Continuing Care Retirement Communities (CCRC) segment reported a growth of 15.9% [3]. Lease Activity - In the reported quarter, Healthpeak executed lab new and renewal leases totaling 276,000 square feet, achieving a retention rate of 88% and +5% cash-releasing spreads on renewals [4]. - For the outpatient medical portfolio, new and renewal leases totaled 973,000 square feet, with a retention rate of 86% and +4% cash-releasing spreads on renewals [4]. Balance Sheet - As of March 31, 2025, Healthpeak had cash and cash equivalents of $70.6 million, down from $119.8 million at the end of 2024, with a net debt to adjusted EBITDAre ratio of 5.2X [5]. - The company repurchased 5.1 million shares at a weighted average price of $18.50, totaling $94 million, from the beginning of the year through April 24 [5]. 2025 Outlook - Healthpeak reaffirmed its guidance for 2025, expecting FFO as adjusted per share to be between $1.81 and $1.87, with the Zacks Consensus Estimate at $1.85 [6]. - The company anticipates total merger-combined same-store cash (adjusted) NOI growth in the range of 3-4% for the year [6].